SCHEMBL314057

SCHEMBL314057

CC(C)(C)OC(=O)N1CCN(CCOC(=O)N2CCN(c3ccccc3)CC2)CC1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 1/20 0.59
HTR1A P08908 3/20 0.52
HTR7 P34969 3/20 0.52
ALDH1A1 P00352 2/20 0.52
MAPT P10636 2/20 0.52
LMNA P02545 1/20 0.52
SIGMAR1 Q99720 1/20 0.51
NAMPT P43490 1/20 0.51
ESRRB O95718 1/20 0.51
ESR1 P03372 1/20 0.51
ESRRA P11474 1/20 0.51
ESRRG P62508 1/20 0.51
CHRM2 P08172 1/20 0.49
CHRM4 P08173 1/20 0.49
CHRM1 P11229 1/20 0.49
CHRM3 P20309 1/20 0.49
DRD2 P14416 2/20 0.49
HTR2A P28223 1/20 0.49
PDK2 Q15119 1/20 0.48
DRD4 P21917 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL313962 0.88 HTR1A (0.57) HTR1AHTR7ALDH1A1MAPTLMNA
SCHEMBL314486 0.86 HTR7 (0.56) HTR1AHTR7ALDH1A1MAPTLMNA
SCHEMBL312796 0.86 CHRNA7 (0.59) HTR1AHTR7ALDH1A1MAPTLMNA
SCHEMBL1458887 0.86 GPR119 (0.76) GPR119ALDH1A1MAPTLMNANAMPT
Hydrochloric Acid SCHEMBL313932 0.85 CHRNA7 (0.57) HTR1AHTR7ALDH1A1MAPTLMNA
SCHEMBL6156057 0.84 GPR119 (0.67) GPR119CHRM4
Formic Acid SCHEMBL314781 0.83 HTR1A (0.52) HTR1AHTR7ALDH1A1MAPTLMNA
SCHEMBL313478 0.81 HTR7 (0.52) HTR1AHTR7ALDH1A1MAPTLMNA
SCHEMBL5235594 0.81 GPR119 (0.69) GPR119ALDH1A1MAPTLMNANAMPT
Hydrochloric Acid SCHEMBL313934 0.81 SIGMAR1 (0.53) HTR1AHTR7ALDH1A1MAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2234992-B1 PIPERAZINE DERIVATIVES AND THEIR USE AS LEPTIN RECEPTOR MODULATORS ASTRAZENECA AB (SE) 2012-02-22 EP disclosed
US-8093248-B2 Compounds useful for the treatment of conditions associated with weight gain ASTRAZENECA AB (PUBL) (SE) 2012-01-10 US disclosed
CN-102015668-A Piperazine derivatives and their use as leptin receptor modulators ASTRAZENECA AB PUBL 2011-04-13 CN disclosed
EP-2234992-A2 PIPERAZINE DERIVATIVES AND THEIR USE AS LEPTIN RECEPTOR MODULATORS AstraZeneca AB (SE) 2010-10-06 EP disclosed
US-20090281087-A1 Compounds II BIOVITRUM AB (SE) 2009-11-12 US disclosed
WO-2009071668-A2 PIPERAZINE DERIVATIVES AND THEIR USE AS LEPTIN RECEPTOR MODULATORS BIOVITRUM AB (PUBL) (SE) 2009-06-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090281087-A1 Compounds II GPR119, FABP4, LIPC GPR119 1/4885HTR1A 1680/4885HTR7 922/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.